Foundation Medicine Projects $12B to $15B Market for Cancer Tests by 2020; Plans Ex-US Launch Soon | GenomeWeb

NEW YORK (GenomeWeb) – Foundation Medicine expects the market for its cancer tests to grow to between $12 billion and $15 billion by 2020. In collaboration with Roche, the company plans to start selling its assays outside the US starting this year.

In the meantime, reimbursement for its tests from private insurers continues to grow. United Healthcare recently published a medical policy under which it will start covering molecular profiling for stage IV non-small cell lung cancer patients in October, which will likely include the firm's FoundationOne test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Dec
06
Sponsored by
Natera

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.